Steven Nissen, MD: Takeaways from the Updated Cholesterol GuidelinesNovember 13th 2018
“These guidelines bring back the concept of adjusting therapy for cholesterol levels, and they recommend more aggressive treatment targets for people in very high risk,” said Cleveland Clinic’s Steven Nissen.
HHS Updates Physical Activity Guidelines for AmericansNovember 12th 2018
The US Department of Health and Human Services updated guidelines feature key recommendations for young children aged 3-5, youths aged 6-17, adults, older adults, pregnant and post-partum women, as well as adults with chronic health conditions and disabilities.
PIONEER-HF: Favorable Results for Sacubitril-Valsartan in Acute Decompensated HFNovember 12th 2018
When compared with enalapril, in patients with acute decompensated heart failure, sacubitril–valsartan led to greater reduction in N-terminal pro–B-type natriuretic peptide (NT-proBNP), and reduced re-hospitalization for heart failure, and was well tolerated.
VITAL Study: Supplements of Omega-3s or Vitamin D Do Not Reduce CVD or CancersNovember 11th 2018
In the VITAL study, investigators found that supplementation with omega-3s and vitamin D did not meet the primary endpoint of significantly reducing major cardiovascular events or total invasive cancer.
Early IVA Conversion Linked to Reduced Vision Loss But At What Cost?October 30th 2018
While it is critical to recognize diabetic macular edema patients with delayed treatment response to reduce the progression of vision loss, improve quality of life, this may come at a cost to the institution.
Four Year Analysis Reports Uptick in Aflibercept Use, Decrease in RanibizumabOctober 29th 2018
After analyzing 57,925 injections administered 2013 and 2017, investigators observed an increase in aflibercept use, with a reciprocal decline in ranibizumab across all regions, while the use of bevacizumab remained stable.